BioMarin Will File 1999 BLA Based On 10-Patient Clinical Package
BioMarin plans to file a BLA this year for its lead compound BM101 based on clinical data from only 10 patients, according to its initial public offering prospectus.
BioMarin plans to file a BLA this year for its lead compound BM101 based on clinical data from only 10 patients, according to its initial public offering prospectus.